 | • レポートコード：MRC308GR11443 • 出版社/出版日：GlobalInfoResearch / 2023年8月 • レポート形態：英文、PDF、104ページ • 納品方法：Eメール（2-3営業日） • 産業分類：医薬品＆ヘルスケア |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
GlobalInfoResearchの最新の調査によると、世界の脂質低下薬の市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
このレポートは、世界の脂質低下薬市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。
市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。
本レポートの主な目的は次のとおりです。
– 世界および主要国の市場機会の規模を決定するため
– 脂質低下薬の成長可能性を評価するため
– 各製品および最終用途市場の将来の成長を予測するため
– 市場に影響を与える競争要因を評価するため
脂質低下薬市場は種類と用途によって区分されます。2018年～2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。
種類別セグメント
・スタチン＆その配合剤、PCSK9阻害剤、胆汁酸封鎖剤、フィブラート系薬剤、コレステロール吸収阻害剤
用途別セグメント
・病院薬局、小売薬局、オンライン薬局
主要な市場プレーヤー
・Sanofi、Pfizer, Inc.、GlaxoSmithKline plc、Novartis AG、Merck & Co., Inc.、Amgen Inc.、Takeda Pharmaceutical Company Limited、Sun Pharmaceutical Industries Ltd.、AbbVie, Inc.、Viatris (Mylan N.V.)、AstraZeneca PLC、Dr. Reddy’s Laboratories Ltd.
地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）
本調査レポートの内容は計15章あります。
・第1章では、脂質低下薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な脂質低下薬メーカーの企業概要、2019年～2022年までの脂質低下薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な脂質低下薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年～2029年までの地域別脂質低下薬の販売量、売上、成長性を示しています。
・第5、6章では、2018年～2029年までの脂質低下薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域での脂質低下薬市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、および脂質低下薬の産業チェーンを掲載しています。
・第14、15章では、脂質低下薬の販売チャネル、販売業者、顧客、調査結果について説明します。
***** 目次(一部) *****
・市場概要
– 脂質低下薬の概要
– 種類別分析（2018年vs2022年vs2029年）：スタチン＆その配合剤、PCSK9阻害剤、胆汁酸封鎖剤、フィブラート系薬剤、コレステロール吸収阻害剤
– 用途別分析（2018年vs2022年vs2029年）：病院薬局、小売薬局、オンライン薬局
– 世界の脂質低下薬市場規模・予測
– 世界の脂質低下薬生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Sanofi、Pfizer, Inc.、GlaxoSmithKline plc、Novartis AG、Merck & Co., Inc.、Amgen Inc.、Takeda Pharmaceutical Company Limited、Sun Pharmaceutical Industries Ltd.、AbbVie, Inc.、Viatris (Mylan N.V.)、AstraZeneca PLC、Dr. Reddy’s Laboratories Ltd.
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・種類別分析2018年-2029年：スタチン＆その配合剤、PCSK9阻害剤、胆汁酸封鎖剤、フィブラート系薬剤、コレステロール吸収阻害剤
・用途別分析2018年-2029年：病院薬局、小売薬局、オンライン薬局
・脂質低下薬の北米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・脂質低下薬のヨーロッパ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・脂質低下薬のアジア市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・脂質低下薬の南米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・脂質低下薬の中東・アフリカ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析）
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論
1 Market Overview
1.1 Product Overview and Scope of Lipid Lowering Drug
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Lipid Lowering Drug Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Statins and Combination
1.3.3 PCSK9 Inhibitors
1.3.4 Bile Acid Sequestrants
1.3.5 Fibrates
1.3.6 Cholesterol Absorption Inhibitors
1.4 Market Analysis by Application
1.4.1 Overview: Global Lipid Lowering Drug Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital Pharmacies
1.4.3 Retail Pharmacies
1.4.4 Online Pharmacies
1.5 Global Lipid Lowering Drug Market Size & Forecast
1.5.1 Global Lipid Lowering Drug Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Lipid Lowering Drug Sales Quantity (2018-2029)
1.5.3 Global Lipid Lowering Drug Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Sanofi
2.1.1 Sanofi Details
2.1.2 Sanofi Major Business
2.1.3 Sanofi Lipid Lowering Drug Product and Services
2.1.4 Sanofi Lipid Lowering Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Sanofi Recent Developments/Updates
2.2 Pfizer, Inc.
2.2.1 Pfizer, Inc. Details
2.2.2 Pfizer, Inc. Major Business
2.2.3 Pfizer, Inc. Lipid Lowering Drug Product and Services
2.2.4 Pfizer, Inc. Lipid Lowering Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Pfizer, Inc. Recent Developments/Updates
2.3 GlaxoSmithKline plc
2.3.1 GlaxoSmithKline plc Details
2.3.2 GlaxoSmithKline plc Major Business
2.3.3 GlaxoSmithKline plc Lipid Lowering Drug Product and Services
2.3.4 GlaxoSmithKline plc Lipid Lowering Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 GlaxoSmithKline plc Recent Developments/Updates
2.4 Novartis AG
2.4.1 Novartis AG Details
2.4.2 Novartis AG Major Business
2.4.3 Novartis AG Lipid Lowering Drug Product and Services
2.4.4 Novartis AG Lipid Lowering Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Novartis AG Recent Developments/Updates
2.5 Merck & Co., Inc.
2.5.1 Merck & Co., Inc. Details
2.5.2 Merck & Co., Inc. Major Business
2.5.3 Merck & Co., Inc. Lipid Lowering Drug Product and Services
2.5.4 Merck & Co., Inc. Lipid Lowering Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Merck & Co., Inc. Recent Developments/Updates
2.6 Amgen Inc.
2.6.1 Amgen Inc. Details
2.6.2 Amgen Inc. Major Business
2.6.3 Amgen Inc. Lipid Lowering Drug Product and Services
2.6.4 Amgen Inc. Lipid Lowering Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Amgen Inc. Recent Developments/Updates
2.7 Takeda Pharmaceutical Company Limited
2.7.1 Takeda Pharmaceutical Company Limited Details
2.7.2 Takeda Pharmaceutical Company Limited Major Business
2.7.3 Takeda Pharmaceutical Company Limited Lipid Lowering Drug Product and Services
2.7.4 Takeda Pharmaceutical Company Limited Lipid Lowering Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates
2.8 Sun Pharmaceutical Industries Ltd.
2.8.1 Sun Pharmaceutical Industries Ltd. Details
2.8.2 Sun Pharmaceutical Industries Ltd. Major Business
2.8.3 Sun Pharmaceutical Industries Ltd. Lipid Lowering Drug Product and Services
2.8.4 Sun Pharmaceutical Industries Ltd. Lipid Lowering Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Sun Pharmaceutical Industries Ltd. Recent Developments/Updates
2.9 AbbVie, Inc.
2.9.1 AbbVie, Inc. Details
2.9.2 AbbVie, Inc. Major Business
2.9.3 AbbVie, Inc. Lipid Lowering Drug Product and Services
2.9.4 AbbVie, Inc. Lipid Lowering Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 AbbVie, Inc. Recent Developments/Updates
2.10 Viatris (Mylan N.V.)
2.10.1 Viatris (Mylan N.V.) Details
2.10.2 Viatris (Mylan N.V.) Major Business
2.10.3 Viatris (Mylan N.V.) Lipid Lowering Drug Product and Services
2.10.4 Viatris (Mylan N.V.) Lipid Lowering Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Viatris (Mylan N.V.) Recent Developments/Updates
2.11 AstraZeneca PLC
2.11.1 AstraZeneca PLC Details
2.11.2 AstraZeneca PLC Major Business
2.11.3 AstraZeneca PLC Lipid Lowering Drug Product and Services
2.11.4 AstraZeneca PLC Lipid Lowering Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 AstraZeneca PLC Recent Developments/Updates
2.12 Dr. Reddy’s Laboratories Ltd.
2.12.1 Dr. Reddy’s Laboratories Ltd. Details
2.12.2 Dr. Reddy’s Laboratories Ltd. Major Business
2.12.3 Dr. Reddy’s Laboratories Ltd. Lipid Lowering Drug Product and Services
2.12.4 Dr. Reddy’s Laboratories Ltd. Lipid Lowering Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Dr. Reddy’s Laboratories Ltd. Recent Developments/Updates
3 Competitive Environment: Lipid Lowering Drug by Manufacturer
3.1 Global Lipid Lowering Drug Sales Quantity by Manufacturer (2018-2023)
3.2 Global Lipid Lowering Drug Revenue by Manufacturer (2018-2023)
3.3 Global Lipid Lowering Drug Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Lipid Lowering Drug by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Lipid Lowering Drug Manufacturer Market Share in 2022
3.4.2 Top 6 Lipid Lowering Drug Manufacturer Market Share in 2022
3.5 Lipid Lowering Drug Market: Overall Company Footprint Analysis
3.5.1 Lipid Lowering Drug Market: Region Footprint
3.5.2 Lipid Lowering Drug Market: Company Product Type Footprint
3.5.3 Lipid Lowering Drug Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Lipid Lowering Drug Market Size by Region
4.1.1 Global Lipid Lowering Drug Sales Quantity by Region (2018-2029)
4.1.2 Global Lipid Lowering Drug Consumption Value by Region (2018-2029)
4.1.3 Global Lipid Lowering Drug Average Price by Region (2018-2029)
4.2 North America Lipid Lowering Drug Consumption Value (2018-2029)
4.3 Europe Lipid Lowering Drug Consumption Value (2018-2029)
4.4 Asia-Pacific Lipid Lowering Drug Consumption Value (2018-2029)
4.5 South America Lipid Lowering Drug Consumption Value (2018-2029)
4.6 Middle East and Africa Lipid Lowering Drug Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Lipid Lowering Drug Sales Quantity by Type (2018-2029)
5.2 Global Lipid Lowering Drug Consumption Value by Type (2018-2029)
5.3 Global Lipid Lowering Drug Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Lipid Lowering Drug Sales Quantity by Application (2018-2029)
6.2 Global Lipid Lowering Drug Consumption Value by Application (2018-2029)
6.3 Global Lipid Lowering Drug Average Price by Application (2018-2029)
7 North America
7.1 North America Lipid Lowering Drug Sales Quantity by Type (2018-2029)
7.2 North America Lipid Lowering Drug Sales Quantity by Application (2018-2029)
7.3 North America Lipid Lowering Drug Market Size by Country
7.3.1 North America Lipid Lowering Drug Sales Quantity by Country (2018-2029)
7.3.2 North America Lipid Lowering Drug Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Lipid Lowering Drug Sales Quantity by Type (2018-2029)
8.2 Europe Lipid Lowering Drug Sales Quantity by Application (2018-2029)
8.3 Europe Lipid Lowering Drug Market Size by Country
8.3.1 Europe Lipid Lowering Drug Sales Quantity by Country (2018-2029)
8.3.2 Europe Lipid Lowering Drug Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Lipid Lowering Drug Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Lipid Lowering Drug Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Lipid Lowering Drug Market Size by Region
9.3.1 Asia-Pacific Lipid Lowering Drug Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Lipid Lowering Drug Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Lipid Lowering Drug Sales Quantity by Type (2018-2029)
10.2 South America Lipid Lowering Drug Sales Quantity by Application (2018-2029)
10.3 South America Lipid Lowering Drug Market Size by Country
10.3.1 South America Lipid Lowering Drug Sales Quantity by Country (2018-2029)
10.3.2 South America Lipid Lowering Drug Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Lipid Lowering Drug Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Lipid Lowering Drug Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Lipid Lowering Drug Market Size by Country
11.3.1 Middle East & Africa Lipid Lowering Drug Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Lipid Lowering Drug Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Lipid Lowering Drug Market Drivers
12.2 Lipid Lowering Drug Market Restraints
12.3 Lipid Lowering Drug Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Lipid Lowering Drug and Key Manufacturers
13.2 Manufacturing Costs Percentage of Lipid Lowering Drug
13.3 Lipid Lowering Drug Production Process
13.4 Lipid Lowering Drug Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Lipid Lowering Drug Typical Distributors
14.3 Lipid Lowering Drug Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Table 1. Global Lipid Lowering Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Lipid Lowering Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Sanofi Basic Information, Manufacturing Base and Competitors
Table 4. Sanofi Major Business
Table 5. Sanofi Lipid Lowering Drug Product and Services
Table 6. Sanofi Lipid Lowering Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Sanofi Recent Developments/Updates
Table 8. Pfizer, Inc. Basic Information, Manufacturing Base and Competitors
Table 9. Pfizer, Inc. Major Business
Table 10. Pfizer, Inc. Lipid Lowering Drug Product and Services
Table 11. Pfizer, Inc. Lipid Lowering Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Pfizer, Inc. Recent Developments/Updates
Table 13. GlaxoSmithKline plc Basic Information, Manufacturing Base and Competitors
Table 14. GlaxoSmithKline plc Major Business
Table 15. GlaxoSmithKline plc Lipid Lowering Drug Product and Services
Table 16. GlaxoSmithKline plc Lipid Lowering Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. GlaxoSmithKline plc Recent Developments/Updates
Table 18. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 19. Novartis AG Major Business
Table 20. Novartis AG Lipid Lowering Drug Product and Services
Table 21. Novartis AG Lipid Lowering Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Novartis AG Recent Developments/Updates
Table 23. Merck & Co., Inc. Basic Information, Manufacturing Base and Competitors
Table 24. Merck & Co., Inc. Major Business
Table 25. Merck & Co., Inc. Lipid Lowering Drug Product and Services
Table 26. Merck & Co., Inc. Lipid Lowering Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Merck & Co., Inc. Recent Developments/Updates
Table 28. Amgen Inc. Basic Information, Manufacturing Base and Competitors
Table 29. Amgen Inc. Major Business
Table 30. Amgen Inc. Lipid Lowering Drug Product and Services
Table 31. Amgen Inc. Lipid Lowering Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Amgen Inc. Recent Developments/Updates
Table 33. Takeda Pharmaceutical Company Limited Basic Information, Manufacturing Base and Competitors
Table 34. Takeda Pharmaceutical Company Limited Major Business
Table 35. Takeda Pharmaceutical Company Limited Lipid Lowering Drug Product and Services
Table 36. Takeda Pharmaceutical Company Limited Lipid Lowering Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Takeda Pharmaceutical Company Limited Recent Developments/Updates
Table 38. Sun Pharmaceutical Industries Ltd. Basic Information, Manufacturing Base and Competitors
Table 39. Sun Pharmaceutical Industries Ltd. Major Business
Table 40. Sun Pharmaceutical Industries Ltd. Lipid Lowering Drug Product and Services
Table 41. Sun Pharmaceutical Industries Ltd. Lipid Lowering Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Sun Pharmaceutical Industries Ltd. Recent Developments/Updates
Table 43. AbbVie, Inc. Basic Information, Manufacturing Base and Competitors
Table 44. AbbVie, Inc. Major Business
Table 45. AbbVie, Inc. Lipid Lowering Drug Product and Services
Table 46. AbbVie, Inc. Lipid Lowering Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. AbbVie, Inc. Recent Developments/Updates
Table 48. Viatris (Mylan N.V.) Basic Information, Manufacturing Base and Competitors
Table 49. Viatris (Mylan N.V.) Major Business
Table 50. Viatris (Mylan N.V.) Lipid Lowering Drug Product and Services
Table 51. Viatris (Mylan N.V.) Lipid Lowering Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Viatris (Mylan N.V.) Recent Developments/Updates
Table 53. AstraZeneca PLC Basic Information, Manufacturing Base and Competitors
Table 54. AstraZeneca PLC Major Business
Table 55. AstraZeneca PLC Lipid Lowering Drug Product and Services
Table 56. AstraZeneca PLC Lipid Lowering Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. AstraZeneca PLC Recent Developments/Updates
Table 58. Dr. Reddy’s Laboratories Ltd. Basic Information, Manufacturing Base and Competitors
Table 59. Dr. Reddy’s Laboratories Ltd. Major Business
Table 60. Dr. Reddy’s Laboratories Ltd. Lipid Lowering Drug Product and Services
Table 61. Dr. Reddy’s Laboratories Ltd. Lipid Lowering Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Dr. Reddy’s Laboratories Ltd. Recent Developments/Updates
Table 63. Global Lipid Lowering Drug Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 64. Global Lipid Lowering Drug Revenue by Manufacturer (2018-2023) & (USD Million)
Table 65. Global Lipid Lowering Drug Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 66. Market Position of Manufacturers in Lipid Lowering Drug, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 67. Head Office and Lipid Lowering Drug Production Site of Key Manufacturer
Table 68. Lipid Lowering Drug Market: Company Product Type Footprint
Table 69. Lipid Lowering Drug Market: Company Product Application Footprint
Table 70. Lipid Lowering Drug New Market Entrants and Barriers to Market Entry
Table 71. Lipid Lowering Drug Mergers, Acquisition, Agreements, and Collaborations
Table 72. Global Lipid Lowering Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 73. Global Lipid Lowering Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 74. Global Lipid Lowering Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 75. Global Lipid Lowering Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 76. Global Lipid Lowering Drug Average Price by Region (2018-2023) & (US$/Unit)
Table 77. Global Lipid Lowering Drug Average Price by Region (2024-2029) & (US$/Unit)
Table 78. Global Lipid Lowering Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 79. Global Lipid Lowering Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 80. Global Lipid Lowering Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 81. Global Lipid Lowering Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 82. Global Lipid Lowering Drug Average Price by Type (2018-2023) & (US$/Unit)
Table 83. Global Lipid Lowering Drug Average Price by Type (2024-2029) & (US$/Unit)
Table 84. Global Lipid Lowering Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 85. Global Lipid Lowering Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 86. Global Lipid Lowering Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 87. Global Lipid Lowering Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 88. Global Lipid Lowering Drug Average Price by Application (2018-2023) & (US$/Unit)
Table 89. Global Lipid Lowering Drug Average Price by Application (2024-2029) & (US$/Unit)
Table 90. North America Lipid Lowering Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 91. North America Lipid Lowering Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 92. North America Lipid Lowering Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 93. North America Lipid Lowering Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 94. North America Lipid Lowering Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 95. North America Lipid Lowering Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 96. North America Lipid Lowering Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 97. North America Lipid Lowering Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 98. Europe Lipid Lowering Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 99. Europe Lipid Lowering Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 100. Europe Lipid Lowering Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 101. Europe Lipid Lowering Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 102. Europe Lipid Lowering Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 103. Europe Lipid Lowering Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 104. Europe Lipid Lowering Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 105. Europe Lipid Lowering Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 106. Asia-Pacific Lipid Lowering Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 107. Asia-Pacific Lipid Lowering Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 108. Asia-Pacific Lipid Lowering Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 109. Asia-Pacific Lipid Lowering Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 110. Asia-Pacific Lipid Lowering Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 111. Asia-Pacific Lipid Lowering Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 112. Asia-Pacific Lipid Lowering Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 113. Asia-Pacific Lipid Lowering Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 114. South America Lipid Lowering Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 115. South America Lipid Lowering Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 116. South America Lipid Lowering Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 117. South America Lipid Lowering Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 118. South America Lipid Lowering Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 119. South America Lipid Lowering Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 120. South America Lipid Lowering Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 121. South America Lipid Lowering Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 122. Middle East & Africa Lipid Lowering Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 123. Middle East & Africa Lipid Lowering Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 124. Middle East & Africa Lipid Lowering Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 125. Middle East & Africa Lipid Lowering Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 126. Middle East & Africa Lipid Lowering Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 127. Middle East & Africa Lipid Lowering Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 128. Middle East & Africa Lipid Lowering Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 129. Middle East & Africa Lipid Lowering Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 130. Lipid Lowering Drug Raw Material
Table 131. Key Manufacturers of Lipid Lowering Drug Raw Materials
Table 132. Lipid Lowering Drug Typical Distributors
Table 133. Lipid Lowering Drug Typical Customers
List of Figures
Figure 1. Lipid Lowering Drug Picture
Figure 2. Global Lipid Lowering Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Lipid Lowering Drug Consumption Value Market Share by Type in 2022
Figure 4. Statins and Combination Examples
Figure 5. PCSK9 Inhibitors Examples
Figure 6. Bile Acid Sequestrants Examples
Figure 7. Fibrates Examples
Figure 8. Cholesterol Absorption Inhibitors Examples
Figure 9. Global Lipid Lowering Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 10. Global Lipid Lowering Drug Consumption Value Market Share by Application in 2022
Figure 11. Hospital Pharmacies Examples
Figure 12. Retail Pharmacies Examples
Figure 13. Online Pharmacies Examples
Figure 14. Global Lipid Lowering Drug Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 15. Global Lipid Lowering Drug Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 16. Global Lipid Lowering Drug Sales Quantity (2018-2029) & (K Units)
Figure 17. Global Lipid Lowering Drug Average Price (2018-2029) & (US$/Unit)
Figure 18. Global Lipid Lowering Drug Sales Quantity Market Share by Manufacturer in 2022
Figure 19. Global Lipid Lowering Drug Consumption Value Market Share by Manufacturer in 2022
Figure 20. Producer Shipments of Lipid Lowering Drug by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 21. Top 3 Lipid Lowering Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 22. Top 6 Lipid Lowering Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 23. Global Lipid Lowering Drug Sales Quantity Market Share by Region (2018-2029)
Figure 24. Global Lipid Lowering Drug Consumption Value Market Share by Region (2018-2029)
Figure 25. North America Lipid Lowering Drug Consumption Value (2018-2029) & (USD Million)
Figure 26. Europe Lipid Lowering Drug Consumption Value (2018-2029) & (USD Million)
Figure 27. Asia-Pacific Lipid Lowering Drug Consumption Value (2018-2029) & (USD Million)
Figure 28. South America Lipid Lowering Drug Consumption Value (2018-2029) & (USD Million)
Figure 29. Middle East & Africa Lipid Lowering Drug Consumption Value (2018-2029) & (USD Million)
Figure 30. Global Lipid Lowering Drug Sales Quantity Market Share by Type (2018-2029)
Figure 31. Global Lipid Lowering Drug Consumption Value Market Share by Type (2018-2029)
Figure 32. Global Lipid Lowering Drug Average Price by Type (2018-2029) & (US$/Unit)
Figure 33. Global Lipid Lowering Drug Sales Quantity Market Share by Application (2018-2029)
Figure 34. Global Lipid Lowering Drug Consumption Value Market Share by Application (2018-2029)
Figure 35. Global Lipid Lowering Drug Average Price by Application (2018-2029) & (US$/Unit)
Figure 36. North America Lipid Lowering Drug Sales Quantity Market Share by Type (2018-2029)
Figure 37. North America Lipid Lowering Drug Sales Quantity Market Share by Application (2018-2029)
Figure 38. North America Lipid Lowering Drug Sales Quantity Market Share by Country (2018-2029)
Figure 39. North America Lipid Lowering Drug Consumption Value Market Share by Country (2018-2029)
Figure 40. United States Lipid Lowering Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Canada Lipid Lowering Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Mexico Lipid Lowering Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 43. Europe Lipid Lowering Drug Sales Quantity Market Share by Type (2018-2029)
Figure 44. Europe Lipid Lowering Drug Sales Quantity Market Share by Application (2018-2029)
Figure 45. Europe Lipid Lowering Drug Sales Quantity Market Share by Country (2018-2029)
Figure 46. Europe Lipid Lowering Drug Consumption Value Market Share by Country (2018-2029)
Figure 47. Germany Lipid Lowering Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. France Lipid Lowering Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. United Kingdom Lipid Lowering Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Russia Lipid Lowering Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Italy Lipid Lowering Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 52. Asia-Pacific Lipid Lowering Drug Sales Quantity Market Share by Type (2018-2029)
Figure 53. Asia-Pacific Lipid Lowering Drug Sales Quantity Market Share by Application (2018-2029)
Figure 54. Asia-Pacific Lipid Lowering Drug Sales Quantity Market Share by Region (2018-2029)
Figure 55. Asia-Pacific Lipid Lowering Drug Consumption Value Market Share by Region (2018-2029)
Figure 56. China Lipid Lowering Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Japan Lipid Lowering Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Korea Lipid Lowering Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. India Lipid Lowering Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Southeast Asia Lipid Lowering Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. Australia Lipid Lowering Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 62. South America Lipid Lowering Drug Sales Quantity Market Share by Type (2018-2029)
Figure 63. South America Lipid Lowering Drug Sales Quantity Market Share by Application (2018-2029)
Figure 64. South America Lipid Lowering Drug Sales Quantity Market Share by Country (2018-2029)
Figure 65. South America Lipid Lowering Drug Consumption Value Market Share by Country (2018-2029)
Figure 66. Brazil Lipid Lowering Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 67. Argentina Lipid Lowering Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 68. Middle East & Africa Lipid Lowering Drug Sales Quantity Market Share by Type (2018-2029)
Figure 69. Middle East & Africa Lipid Lowering Drug Sales Quantity Market Share by Application (2018-2029)
Figure 70. Middle East & Africa Lipid Lowering Drug Sales Quantity Market Share by Region (2018-2029)
Figure 71. Middle East & Africa Lipid Lowering Drug Consumption Value Market Share by Region (2018-2029)
Figure 72. Turkey Lipid Lowering Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Egypt Lipid Lowering Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Saudi Arabia Lipid Lowering Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. South Africa Lipid Lowering Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 76. Lipid Lowering Drug Market Drivers
Figure 77. Lipid Lowering Drug Market Restraints
Figure 78. Lipid Lowering Drug Market Trends
Figure 79. Porters Five Forces Analysis
Figure 80. Manufacturing Cost Structure Analysis of Lipid Lowering Drug in 2022
Figure 81. Manufacturing Process Analysis of Lipid Lowering Drug
Figure 82. Lipid Lowering Drug Industrial Chain
Figure 83. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 84. Direct Channel Pros & Cons
Figure 85. Indirect Channel Pros & Cons
Figure 86. Methodology
Figure 87. Research Process and Data Source